Evie Yulin - Merck Tbk Biopharma Director

MERK Stock  IDR 3,990  30.00  0.76%   

Director

Ms. Evie Yulin serves as Biopharma Director of PT Merck Tbk since January 2011. She is a Pharmacist with both undergraduate and postgraduate qualifications from the Faculty of Pharmacy, Universitas Gadjah Mada, Indonesia. She built a professional career through various senior executive positions, at a number of pharmaceutical companies in Indonesia and in regional platform for handling some projects. She built her career by joining Bayer Indonesia and then joining two local companies as the Business Development and Product Manager. She continued her career in Roche Indonesia with various responsibilities and key achievements, then worked with PT Aventis Pharma as Marketing Director and as Business Unit Director at PT Astra Zeneca Indonesia. since 2011.
Age 56
Tenure 13 years
Phone62 21 2856 5600
Webhttps://www.merckgroup.com/id-id

Merck Tbk Management Efficiency

The company has return on total asset (ROA) of 0.1573 % which means that it generated a profit of $0.1573 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2334 %, meaning that it generated $0.2334 on every $100 dollars invested by stockholders. Merck Tbk's management efficiency ratios could be used to measure how well Merck Tbk manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 13.12 B in total debt with debt to equity ratio (D/E) of 0.04, which may suggest the company is not taking enough advantage from borrowing. Merck Tbk has a current ratio of 3.64, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Merck Tbk until it has trouble settling it off, either with new capital or with free cash flow. So, Merck Tbk's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Merck Tbk sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Merck to invest in growth at high rates of return. When we think about Merck Tbk's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 11 records

DIRECTOR Age

HartonoIndonesia Prima Property
54
Billie FuliangsaharIndonesia Prima Property
N/A
Martha SusantiMinna Padi Investama
53
Iwan SantosoIndonesia Prima Property
N/A
Devin RidwanProvident Agro Tbk
48
Euodia DewayantiDanasupra Erapacific Tbk
54
Harianda NoerlanFirst Media Tbk
60
Agus GozaliIndonesia Prima Property
50
Tjie SetiadiOnix Capital Tbk
45
Njudarsono YusetijoIndonesia Prima Property
59
Chandraja HaritaIndonesia Prima Property
44
PT Merck Tbk manufactures and sells pharmaceutical products in Indonesia. The company was founded in 1970 and is headquartered in East Jakarta, Indonesia. Merck Tbk operates under Drug ManufacturersSpecialty Generic classification in Indonesia and is traded on Jakarta Stock Exchange. It employs 405 people. Merck Tbk (MERK) is traded on Jakarta Exchange in Indonesia and employs 393 people.

Management Performance

Merck Tbk Leadership Team

Elected by the shareholders, the Merck Tbk's board of directors comprises two types of representatives: Merck Tbk inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck Tbk's management team and ensure that shareholders' interests are well served. Merck Tbk's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck Tbk's outside directors are responsible for providing unbiased perspectives on the board's policies.
Arryo Wachjuwidajat, Independent Director, Plant Director
Melisa Sandrianti, Corporate Secretary
Parulian Simanjuntak, Independent Commissioner
Aquira Moeladi, Human Head
Pachita Ramadhani, Head Mang
Bambang Nurcahyo, Finance Director
Rinita Daniati, Head Legal
Mei Tang, President Commissioner
Eduan Tjong, Supply Mang
Martin Feulner, President Director
Miranda Andamsari, Compliance Officer
Eza Evariza, Accounting Mang
Evie Yulin, Biopharma Director

Merck Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck Tbk a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Tbk. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for Merck Stock analysis

When running Merck Tbk's price analysis, check to measure Merck Tbk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck Tbk is operating at the current time. Most of Merck Tbk's value examination focuses on studying past and present price action to predict the probability of Merck Tbk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck Tbk's price. Additionally, you may evaluate how the addition of Merck Tbk to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Equity Valuation
Check real value of public entities based on technical and fundamental data
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Please note, there is a significant difference between Merck Tbk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck Tbk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck Tbk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.